<DOC>
	<DOC>NCT00050947</DOC>
	<brief_summary>This study will evaluate the safety and effectiveness of oxcarbazepine (Trileptal) as monotherapy in the treatment of partial seizures in pediatric patients 1 month to 3 years of age.</brief_summary>
	<brief_title>Pediatric Epilepsy Study</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Oxcarbazepine</mesh_term>
	<mesh_term>Carbamazepine</mesh_term>
	<criteria>INCLUSION CRITERIA: To enter this study, patients must: Have a diagnosis of partial seizures Have 230 seizures per week while on a stable dose of one antiepileptic drug or be a patient recently diagnosed with partial seizures and currently receiving no seizure medication Be willing to be hospitalized for up to 5 days Weigh a minimum of 6.6 lbs Have had a previous CAT scan/MRI confirming the absence of space occupying lesions or progressive neurological disease Have normal laboratory results EXCLUSION CRITERIA: To enter this study, a patient must not have or be: Seizures caused by metabolic disturbance, toxic exposure, or active infection A primary diagnosis of generalized epilepsy (exception secondarily generalized seizures) A history of status epilepticus within 30 days Seizures not related to epilepsy This study has some AED restrictions Serum sodium levels &lt;135 mEq/L Significant heart, breathing, kidney, stomach, liver, blood, or cancer disorder requiring treatment/therapy A history of chronic infection (e.g., hepatitis or HIV) Significant electrocardiogram (ECG) abnormalities A nursing mother taking anticonvulsant drugs A history of substance abuse (including alcohol) Previously demonstrated sensitivity/allergic reaction to Trileptal or related compounds Used experimental medication within 30 days of entering this study</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>partial seizures</keyword>
</DOC>